$0.20
4.76%
Nasdaq, Wed, Apr 02 2025
ISIN
US75973T1016
Symbol
RNLX

Renalytix Plc - ADR Stock price

$0.20
-0.07 24.53% 1M
+0.01 4.66% 6M
-0.01 4.81% YTD
-0.65 76.47% 1Y
-6.81 97.15% 3Y
-13.30 98.52% 5Y
-13.30 98.52% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.01 4.76%
ISIN
US75973T1016
Symbol
RNLX

Key metrics

Market capitalization $34.78m
Enterprise Value $33.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.08
P/S ratio (TTM) P/S ratio 14.68
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -1.58%
Revenue (TTM) Revenue $2.37m
EBIT (operating result TTM) EBIT $-20.11m
Free Cash Flow (TTM) Free Cash Flow $-26.50m
Cash position $9.63m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 3.24
EV/Sales forward 4.12
Short interest 1.52%
Show more

Is Renalytix Plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Renalytix Plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Renalytix Plc - ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Renalytix Plc - ADR:

Buy
100%

Financial data from Renalytix Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2.37 2.37
2% 2%
100%
- Direct Costs 1.90 1.90
16% 16%
80%
0.66 0.66
340% 340%
28%
- Selling and Administrative Expenses 21 21
16% 16%
868%
- Research and Development Expense - -
-
-
-20 -20
47% 47%
-842%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -20 -20
47% 47%
-849%
Net Profit -23 -23
44% 44%
-989%

In millions USD.

Don't miss a Thing! We will send you all news about Renalytix Plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in Penarth, the United Kingdom.

Head office United Kingdom
CEO James McCullough
Founded 2018
Website renalytix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today